MSD shocked over medicines council: "We have a system that doesn't work"
Pharmaceutical company MSD is puzzled by the Danish Medicines Council's choice to temporarily halt its reassessment of the firm's cancer remedy Keytruda in a specific lung indication after a meeting on Wednesday, even though it's now been two years since the European Medicines Agency approved the drug.
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY JONAS SAHL JØRGENSEN
Pharmaceutical company MSD once again has to prepare for a waiting period prior to knowing whether the Danish Medicines Council will approve its big seller, cancer remedy Keytruda (pembrolizumab) targeting a particular type of lung cancer.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Danish Medicines Council’s new methods sent to hearing
For abonnenter
